Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.

CONCLUSIONS: Some patients may benefit from continuation of gefitinib beyond PD.
PMID: 29871540 [PubMed - as supplied by publisher]

Source: Expert Opinion on Pharmacotherapy - June 8, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research